Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) saw a significant decrease in short interest in January. As of January 15th, there was short interest totalling 25,020,000 shares, a decrease of 20.5% from the December 31st total of 31,470,000 shares. Based on an average trading volume of 9,750,000 shares, the days-to-cover ratio is currently 2.6 days.
Wall Street Analysts Forecast Growth
TEVA has been the subject of a number of recent analyst reports. BMO Capital Markets decreased their target price on Teva Pharmaceutical Industries from $11.00 to $10.00 and set a "market perform" rating for the company in a report on Monday, November 7th. Piper Sandler reduced their price target on Teva Pharmaceutical Industries from $8.00 to $7.00 and set an "underweight" rating on the stock in a research note on Wednesday, November 23rd. StockNews.com started coverage on Teva Pharmaceutical Industries in a research note on Wednesday, October 12th. They issued a "buy" rating on the stock. UBS Group cut Teva Pharmaceutical Industries from a "neutral" rating to a "sell" rating in a research note on Friday, November 4th. Finally, JPMorgan Chase & Co. cut Teva Pharmaceutical Industries from a "neutral" rating to an "underweight" rating and reduced their price target for the stock from $11.00 to $10.00 in a research note on Monday, November 14th. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $10.67.
Get Teva Pharmaceutical Industries alerts:Teva Pharmaceutical Industries Stock Up 1.1 %
Shares of NYSE TEVA traded up $0.11 during trading on Friday, reaching $10.38. The company had a trading volume of 7,738,661 shares, compared to its average volume of 9,882,554. Teva Pharmaceutical Industries has a 12-month low of $6.78 and a 12-month high of $11.44. The stock has a market cap of $11.53 billion, a PE ratio of -8.95 and a beta of 1.20. The business's 50-day moving average is $9.51 and its 200 day moving average is $9.10. The company has a quick ratio of 0.66, a current ratio of 0.99 and a debt-to-equity ratio of 1.94.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last released its earnings results on Thursday, November 3rd. The company reported $0.56 EPS for the quarter, missing analysts' consensus estimates of $0.58 by ($0.02). Teva Pharmaceutical Industries had a positive return on equity of 26.97% and a negative net margin of 8.52%. The company had revenue of $3.60 billion during the quarter, compared to analysts' expectations of $3.86 billion. As a group, equities analysts forecast that Teva Pharmaceutical Industries will post 2.4 earnings per share for the current fiscal year.Institutional Investors Weigh In On Teva Pharmaceutical Industries
Institutional investors have recently modified their holdings of the business. Ronald Blue Trust Inc. boosted its position in shares of Teva Pharmaceutical Industries by 1,232.2% during the fourth quarter. Ronald Blue Trust Inc. now owns 3,677 shares of the company's stock valued at $30,000 after buying an additional 3,401 shares during the last quarter. Private Trust Co. NA purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter valued at $32,000. Credit Agricole S A purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter valued at $34,000. Newbridge Financial Services Group Inc. boosted its position in shares of Teva Pharmaceutical Industries by 555.6% during the third quarter. Newbridge Financial Services Group Inc. now owns 5,900 shares of the company's stock valued at $48,000 after buying an additional 5,000 shares during the last quarter. Finally, Edmond DE Rothschild Holding S.A. boosted its position in shares of Teva Pharmaceutical Industries by 213.8% during the third quarter. Edmond DE Rothschild Holding S.A. now owns 6,678 shares of the company's stock valued at $54,000 after buying an additional 4,550 shares during the last quarter. 50.39% of the stock is owned by hedge funds and other institutional investors.
Teva Pharmaceutical Industries Company Profile
(Get Rating)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.
Recommended Stories
- Get a free copy of the StockNews.com research report on Teva Pharmaceutical Industries (TEVA)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.